(PDF) A Critical Review on the Dosing and Safety of Antifungals Used in Exotic Avian and Reptile
THE PHARMACOLOGY AND EFFICACY OF ANTIFUNGALS: A LITERATURE REVIEW
Antifungal Dosing in Obesity, Dr Haifa Lyster
Recommendations for the use and dosing of specific antifungal agents...
ANTIFUNGALS
Antifungals
VIDEO
Antimicrobial Dosing in Obesity
Antifungal Dosing in Obesity, Dr Haifa Lyster
Antibacterial dosing in obesity
Aqualine Water treatment unit
Considerations for Conditioning Chemotherapy Dosing in Obesity
Antifungals (All you need to Know in a Single Mnemonic)
COMMENTS
Dosing Antifungals in Obesity: a Literature Review | Current ...
To summarize the available evidence regarding antifungaldosinginobese adults as well as to provide meaningful guidance on the dosing of each antifungal agent in obese patients.
Antifungal Dosing in Obesity: A Review of the Literature
This article reviews the available literature on the dosing of antifungal agents in obese patients. Pharmacokinetic Considerations in Obesity. The effects of obesity on human pharmacokinetics and the impact of these changes on multiple drugs and drug classes have been extensively reviewed [3 – 5 •, 6 – 9].
Dosing of antifungal agents in obese people - PubMed
Systemic antifungal therapy for invasive candidiasis continues to have a high failure rate, and dose optimization in obesity provides an opportunity for improvement. Based on currently available data, some antifungals should be dosed based on total body weight (i.e. fluconazole), while others should not be adjusted for increased body weight (i ...
Dosing Antifungals in Obesity: a Literature Review
In this review, we examine the current limitations and practical issues of adapting a pharmacometrics-guided dosing approaches to dosing of antifungalsin critically ill or severely ...
Dosing Antifungals in Obesity: a Literature Review
TLDR. Fluconazole and voriconazole dosing should be based on total body weight and adjusted body weight, respectively, and echinocandin doses likely need to be increased in obese patients, but the exact weight and dosages remain elusive. Expand.
Antifungal Dosing in Obesity: A Review of the Literature
This review discusses the changes in pharmacokinetics that occur in obesity and the available in vitro and in vivo data describing the disposition of antifungal agents in obese animals and...
Dosing Antifungals in Obesity: a Literature Review
It is well known that obesity is a worldwide problem. In 2015–2016, obesity affected 39.8% of adults and 18.5% of children 2–19 years of age in the
Dosing of antifungal agents in obese people: Expert Review of ...
Based on currently available data, some antifungals should be dosed based on total body weight (i.e. fluconazole), while others should not be adjusted for increased body weight (i.e. posaconazole). More studies are needed to determine if and when dosing changes are needed for many of the antifungal agents.
Updated antimicrobial dosing recommendations for obese ...
This is a comprehensive review of the dosing of different types of antimicrobials (antibiotics, antifungals, antivirals, and antituberculosis drugs) in obese patients, where the literature on PK and possible dosing strategies in obese adults was critically assessed.
Dosing Antifungals in Obesity: a Literature Review - Springer
Purpose of Review To summarize the available evidence regarding antifungaldosinginobese adults as well as to provide meaningful guidance on the dosing of each antifungal agent in obese patients. Recent Findings The pharmacokinetic evidence regarding dosing antifungal agents in obesity is limited.
IMAGES
VIDEO
COMMENTS
To summarize the available evidence regarding antifungal dosing in obese adults as well as to provide meaningful guidance on the dosing of each antifungal agent in obese patients.
This article reviews the available literature on the dosing of antifungal agents in obese patients. Pharmacokinetic Considerations in Obesity. The effects of obesity on human pharmacokinetics and the impact of these changes on multiple drugs and drug classes have been extensively reviewed [3 – 5 •, 6 – 9].
Systemic antifungal therapy for invasive candidiasis continues to have a high failure rate, and dose optimization in obesity provides an opportunity for improvement. Based on currently available data, some antifungals should be dosed based on total body weight (i.e. fluconazole), while others should not be adjusted for increased body weight (i ...
In this review, we examine the current limitations and practical issues of adapting a pharmacometrics-guided dosing approaches to dosing of antifungals in critically ill or severely ...
TLDR. Fluconazole and voriconazole dosing should be based on total body weight and adjusted body weight, respectively, and echinocandin doses likely need to be increased in obese patients, but the exact weight and dosages remain elusive. Expand.
This review discusses the changes in pharmacokinetics that occur in obesity and the available in vitro and in vivo data describing the disposition of antifungal agents in obese animals and...
It is well known that obesity is a worldwide problem. In 2015–2016, obesity affected 39.8% of adults and 18.5% of children 2–19 years of age in the
Based on currently available data, some antifungals should be dosed based on total body weight (i.e. fluconazole), while others should not be adjusted for increased body weight (i.e. posaconazole). More studies are needed to determine if and when dosing changes are needed for many of the antifungal agents.
This is a comprehensive review of the dosing of different types of antimicrobials (antibiotics, antifungals, antivirals, and antituberculosis drugs) in obese patients, where the literature on PK and possible dosing strategies in obese adults was critically assessed.
Purpose of Review To summarize the available evidence regarding antifungal dosing in obese adults as well as to provide meaningful guidance on the dosing of each antifungal agent in obese patients. Recent Findings The pharmacokinetic evidence regarding dosing antifungal agents in obesity is limited.